GCM Grosvenor Holdings LLC Sells 6,475 Shares of Natera, Inc. $NTRA

GCM Grosvenor Holdings LLC decreased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 8.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 68,732 shares of the medical research company’s stock after selling 6,475 shares during the quarter. Natera accounts for about 1.7% of GCM Grosvenor Holdings LLC’s investment portfolio, making the stock its 12th biggest position. GCM Grosvenor Holdings LLC owned 0.05% of Natera worth $11,612,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Park Avenue Securities LLC bought a new position in shares of Natera in the second quarter worth about $1,525,000. Atria Investments Inc boosted its position in Natera by 30.1% in the 2nd quarter. Atria Investments Inc now owns 13,242 shares of the medical research company’s stock valued at $2,237,000 after buying an additional 3,063 shares during the period. Zweig DiMenna Associates LLC grew its stake in Natera by 3.0% in the 2nd quarter. Zweig DiMenna Associates LLC now owns 124,100 shares of the medical research company’s stock worth $20,965,000 after acquiring an additional 3,610 shares in the last quarter. Baird Financial Group Inc. increased its position in shares of Natera by 277.8% during the second quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock worth $4,498,000 after acquiring an additional 19,576 shares during the period. Finally, Comerica Bank raised its stake in shares of Natera by 24.1% during the first quarter. Comerica Bank now owns 141,106 shares of the medical research company’s stock valued at $19,954,000 after acquiring an additional 27,379 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Roelof Botha sold 75,000 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $236.12, for a total transaction of $17,709,000.00. Following the transaction, the director directly owned 1,154,198 shares of the company’s stock, valued at approximately $272,529,231.76. This represents a 6.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Roy D. Baynes sold 7,668 shares of the stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $223.08, for a total value of $1,710,577.44. Following the sale, the director owned 18,359 shares of the company’s stock, valued at approximately $4,095,525.72. This represents a 29.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 312,053 shares of company stock valued at $64,527,735 over the last quarter. Insiders own 5.63% of the company’s stock.

Analyst Upgrades and Downgrades

NTRA has been the topic of several research analyst reports. Wells Fargo & Company increased their price objective on Natera from $175.00 to $190.00 and gave the stock an “equal weight” rating in a research note on Friday, November 7th. BNP Paribas raised Natera to a “hold” rating and set a $172.00 price target on the stock in a research report on Monday, October 27th. Zacks Research lowered Natera from a “hold” rating to a “strong sell” rating in a research note on Monday, October 20th. Morgan Stanley upped their price objective on shares of Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Finally, BTIG Research raised their target price on shares of Natera from $230.00 to $260.00 and gave the company a “buy” rating in a research report on Friday, December 5th. Fifteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $225.29.

Natera Price Performance

NTRA opened at $231.95 on Friday. The firm has a market capitalization of $32.08 billion, a PE ratio of -101.29 and a beta of 1.63. The business’s 50-day moving average is $206.71 and its two-hundred day moving average is $176.50. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $246.90.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same quarter in the prior year, the business posted ($0.26) earnings per share. The firm’s quarterly revenue was up 34.7% on a year-over-year basis. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.